Orbis Biosciences Acquisition by Adare Pharmaceuticals

Client News

May 4, 2020

Gunderson Dettmer client Orbis Biosciences, a pharmaceutical company that integrates technology to create products that are safer and more effective than current treatment options, was acquired by Adare Pharmaceuticals.

In the announcement of the transaction president and CEO of Orbis Biosciences Maria Flynn said, "The acquisition by Adare will globalize the reach of our technologies and services. Orbis's focus on precision delivery solutions has enabled us to develop expertise in novel extended-release and pulsatile-release formulations and to collaborate with great partners. We are pleased to join Adare, an industry leader in drug formulation development and manufacturing."

The Gunderson Dettmer deal team included Colman Lynch, Valdemar Washington, Caroline Ceriello and Piper Miles-Coccaro.

Related People

Colman L. Lynch
PARTNER
P +1 212 430 3163

Caroline K. Ceriello
ASSOCIATE
P +1 646 490 9016

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces $30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces $20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces $100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces $87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces $356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in "Where the legal battle stands around copyright and AI training"

CLIENT NEWS

Latin America Fintech Belvo Announces $15M Funding